Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Stopped early

Conditions studied: Solid and Hematological Malignancies

In brief

Subjects who previously took part in an Adaptimmune study and received genetically changed T cells (including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T) are asked to take part in this long term follow-up study. Subjects will be asked to join this study once they complete the parent interventional study. The purpose of this study is to find out if the genetically changed T cells that subjects received in the parent study have any long-term side effects. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from last administration of the genetically changed T cells, subjects will visit their study doctor for a check-up and to have blood tests to look for any changes that might have happened because of the genetically changed T cells.

Key facts

Study ID

NCT03391791

Run by

Adaptimmune

People needed

2

Starts

2018-02-28

Expected to finish

2018-07-24

Last updated by the study team

2021-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have received T cell receptor therapy in an Adaptimmune clinical study
• Subjects who have provided informed consent prior to their study participation

You may not qualify if…

• Not applicable

Where it is running

• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Princess Margaret Cancer Centr — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.